Engredea News  Analysis

JDS Therapeutics completes $16 million financing deal

JDS Therapeutics and its subsidiary, Nutrition 21, will accelerate the companies' specialty pharmaceutical and nutritional ingredient businesses with the funding, which was led by 1315 Capital.

JDS Therapeutics, LLC, a privately held, specialty pharmaceutical company and its Nutrition 21, LLC, nutritional ingredient subsidiary, announced Thursday that it has closed a $16 million Series B institutional equity financing round led by 1315 Capital, a Philadelphia-based investment firm specializing in healthcare.

"We are delighted to welcome 1315 Capital to our investor group. This $16 million financing will allow us to support and accelerate our high growth specialty pharmaceutical and nutritional ingredient business platforms. In addition, we expect to continue our strong investment commitment to the protection and expansion of our substantial intellectual property portfolio,” said Michael Satow, president and CEO of JDS.

Michael Koby, a partner at 1315 Capital, said, “1315 Capital is excited to be partnering with the JDS team. We are highly enthusiastic about the growth prospects and opportunities within the company’s multiple business platforms.”

JDS Therapeutics, LLC, develops and manufactures women’s health products. Nutrition 21 develops high-value, clinically substantiated ingredients for dietary supplements, medical foods and beverages, such asChromax chromium picolinate and Nitrosigine bonded arginine silicate.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.